MedDataX Logo

Bioequivalence Study of Gabapentin 400 mg Capsules Under Fed Conditions

NCT ID: NCT00778765

Last Updated: 2008-10-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

24 participants

Study Classification

INTERVENTIONAL

Study Start Date

2002-09-30

Study Completion Date

2002-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To compare the single-dose oral bioavailability of metformin HCI liquid 500 mg/5 mL of Ranbaxy with Glucophage® 1000 mg tablets of Bristol-Myers, USA following administration of a 1000 mg dose in healthy, adult, male and female volunteers under fasting conditions

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This was an open-label, randomized, single-dose, 2-way crossover, relative bioavailability study performed on 24 healthy adult volunteers and 2 alternates. All 26 subjects completed the clinical phase of the study. In each period, subjects were housed from the evening before dosing until after the 36-hour blood draw. Single oral 400 mg doses were separated by a washout period of 7 days A total of 24 healthy adult volunteers and 2 alternates (17 males and 9 non-pregnant females) enrolled in and completed the clinical phase of the study

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Bioequivalence gabapentin fed conditions

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

400 mg Gabapentin Capsules of Ranbaxy

Group Type EXPERIMENTAL

400 mg Gabapentin Capsules

Intervention Type DRUG

2

Neurontin® 400 mg Gabapentin Capsules

Group Type ACTIVE_COMPARATOR

400 mg Gabapentin Capsules

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

400 mg Gabapentin Capsules

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Healthy adult male or female volunteers, 18-55 years of age
2. Weighing at least 52 kg for males and 45 kg for females and within 15% of their ideal weights (Table of "Desirable Weights of Adults", Metropolitan Life Insurance Company, 1983)
3. Medically healthy subjects with clinically normal laboratory profiles
4. Females of childbearing potential should either be sexually inactive (abstinent) for 14 days prior to the study and throughout the study or be using one of the following acceptable birth control methods:

* surgically sterile (bilateral tubal ligation, hysterectomy bilateral oophorectomy) 6 months minimum
* IUD in place for at least 3 months
* barrier methods (condom, diaphragm) with spermicide for at least 14 days prior to the start of the study and throughout the study
* surgical sterilization of the partner (vasectomy for 6 months minimum)
* hormonal contraceptives for at least 3 months prior to the start of the study

Other birth control methods may be deemed acceptable. Postmenopausal women with amenorrhea for at least 2 years will be eligible.
5. Voluntarily consent to participate in the study.

Exclusion Criteria

Subject candidates must not be enrolled in the study if they meet any of the following criteria:

1. History or presence of significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or psychiatric disease
2. In addition, history or presence of:

* alcoholism or drug abuse within the past 2 years
* hypersensitivity or idiosyncratic reaction to anticonvulsants
3. Female subjects who are pregnant or lactating
4. Subjects who have been on an abnormal diet (for whatever reason) during the 30 days prior to the first dose
5. Subjects who, through completion of the study, would have donated in excess of:

* 500 mL of blood in 14 days, or
* 500 - 750 mL of blood in 14 days (unless approved by the Principal Investigator)
* 1000 mL of blood in 90 days
* 1250 mL of blood in 12 days
* 1500 mL of blood in 180 days
* 2000 mL of blood in 270 days
* 2500 mL of blood in I year
6. Subjects who have participated in another clinical trial within 28 days prior to the first dose
Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ranbaxy Laboratories Limited

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Ranbaxy Research Labs

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

MDS Pharma Services

Saint-Laurent, Quebec, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Canada

Related Links

Access external resources that provide additional context or updates about the study.

http://clinicalstudies.ranbaxy.com

Related Info

http://dailymed.nlm.nih.gov/dailymed/about.cfm

Related Info

http://www.fda.gov/opacom/7alerts.html

Related Info

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

AA01820

Identifier Type: -

Identifier Source: org_study_id